CEO Today USA Awards

www.ceotodaymagazine.com 76 CEO Today USAAwards 2018 MASSACHUSETTS JENS ECKSTEIN President of SR – One ABOUT JENS ECKSTEIN Jens Eckstein has been President of SR One since 2011. He joined SR One from TVM Capital where he was last venture partner, entrepreneur-in-residence, and appointed CEO and president of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVM’s Boston life sciences practice where he focused on earlier- stage investments in innovative and emerging biopharma start-up companies. Prior to joining TVM Capital and the investment world, he led drug discovery programs at Enanta Pharmaceuticals and Mitotix. Jens is currently a board director at Palleon Pharmaceuticals, Decibel Therapeutics, ZappRx, Gladius Pharmaceuticals, and BioHealth Innovation (BHI). He was previously a member of the board of directors for Alios Biosciences (acquired by Johnson & Johnson), CoNCERT Pharmaceuticals (NASDAQ: CNCE), Enanta Pharmaceuticals (NASDAQ: ENTA), SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an advisor and board observer to Sirtris Pharmaceuticals (acquired by GSK). Jens is a biological chemist by training gaining his Ph.D. studying the enzyme mechanism of bacterial luciferase at University of Konstanz, Germany, and Harvard University. He was a post-doctoral fellow at UCSF focusing on rational drug design. He is the author of multiple scientific publications and holds several issued and pending patents. As a Kauffman Fellow and angel investor Jens enjoys mentoring young entrepreneurs. He co- created ‘OneStart’, the largest life science business accelerator competition in the world. Jens lives with his family in Cambridge, Massachusetts. FIRM PROFILE SR One is the independent corporate venture capital group of GlaxoSmithKline (GSK). Our remit is to identify and foster break-through innovation in the life sciences and healthcare. The firm invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One’s team of investment professionals, located in the US (Boston, San Francisco and Mid- Atlantic) and UK (London), has experience spanning basic and innovative science, pre- clinical and clinical drug development, and early commercialization. We take an active role in our portfolio companies, and work with management teams and our fellow venture investors to create significant value for both, investors and patients. SR One’s deep network into the global innovation ecosystem has backed exciting novel science such as RNA-based therapeutics, next- generation anti-infectives or CRSIPR-based drugs, and built and syndicated companies with the premier life science venture investors and brilliant scientists. Webackpassionate foundersandentrepreneurs to develop transformative medicines, from lab bench to patient bedside. In its more than 35 year history, SR One has invested over $1.2 billion in more than 180 companies. SR One’s current portfolio includes over 40 private and public investments. www.srone.com “As a Kauffman Fellow and angel investor Jens enjoys mentoring young entrepreneurs. He co- created ‘OneStart’, the largest life science business accelerator competition in the world.”